Intrinsic Value of S&P & Nasdaq Contact Us

iRhythm Technologies, Inc. IRTC NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
58/100
4/7 Pass
SharesGrow Intrinsic Value
$1,387.90
+1026.3%
Analyst Price Target
$210.91
+71.2%

iRhythm Technologies, Inc. (IRTC) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 16 Buy, 3 Hold.

The consensus price target is $210.91 (low: $184.00, high: $244.00), representing an upside of 71.2% from the current price $123.23.

Analysts estimate Earnings Per Share (EPS) of $-3.67 and revenue of $0.59B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-3.63 vs est $-3.67 (beat +1.1%). 2025: actual $-1.39 vs est $-1.50 (beat +7.4%). Analyst accuracy: 95%.

IRTC Stock — 12-Month Price Forecast

$210.91
▲ +71.15% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for iRhythm Technologies, Inc., the average price target is $210.91, with a high forecast of $244.00, and a low forecast of $184.00.
The average price target represents a +71.15% change from the last price of $123.23.
Highest Price Target
$244.00
Average Price Target
$210.91
Lowest Price Target
$184.00

IRTC Analyst Ratings

Buy
19
Ratings
16 Buy
3 Hold
Based on 19 analysts giving stock ratings to iRhythm Technologies, Inc. in the past 3 months
Rating breakdown
Buy
16 84%
Hold
3 16%
84%
Buy
16 analysts
16%
Hold
3 analysts
0%
Sell
0 analysts

EPS Estimates — IRTC

95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$3.63 vs Est –$3.67 ▲ 1.1% off
2025 Actual –$1.39 vs Est –$1.50 ▲ 8.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — IRTC

99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.592B vs Est $0.585B ▲ 1.1% off
2025 Actual $0.747B vs Est $0.740B ▲ 1.0% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message